Table 2 IGEST final version and CVI second-round score

Preliminary condition

 a. The full disclosure of any financial conflict of interest (COI) for each decision voted by panellists is reported.

13

 b. The strategy for systematic review of the literature (i.e., search strategy and study selection) is clearly described.

14

 c. A full description of the affiliation and professional profile of panellists is reported.

14

 d. The external review carried out by independent experts is reported.

12

Dimension 1. Conflict of interest

 1. The guideline should describe how any identified conflicts were recorded and resolved.

12

 2. Non-financial COI is managed.

11

 3. COI of any guideline development group members are examined and managed by an oversight committee.

12

 4. Chair and co-chair are not allowed to have any relevant² financial COI.

11

Dimension 2. Quality and consistency

 5. Quality of evidence is rated according to study type, and there is no explicit link between quality of evidence and strength of recommendations.

14

 6. Quality of evidence is rated according to study type, and there is an explicit link between the quality of evidence and strength of recommendations.

13

 7. Quality of evidence is rated according to both study type and risk of bias, and there is an explicit link between the quality of evidence and strength of recommendations.

11

 8. Rating quality of evidence and grading strength of recommendations are based on GRADE or GRADE-like method.

14

Dimension 3. Panel composition

 9. Only one clinical specialty is involved.

12

 10. More than one clinical specialty is involved.

12

 11. Different relevant clinical specialities, general practitioners, and other professional groups are involved.

13

 12. Different relevant clinical specialities, general practitioners, other professional groups, and at least one patient representative are involved.

14